Drugs / Becotatug Vedotin
Becotatug Vedotin
also known as
MRG003 · Anti-egfr adc mrg003 · Becotatug vedotina · Becotatug vedotine · Vebecototagene Autoteucovaline
Monoclonal antibody targets EGFR
Trials 57 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07697040 | Jul 2026 → Jul 2029 expected | esophageal squamous cell carcinoma | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07584499 | May 2026 → May 2027 expected | Wilms tumor, atypical teratoid rhabdoid tumor, diffuse intrinsic pontine glioma, head and neck squamous cell carcinoma +5 | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1 | NCT07054307 | Feb → Jul 2026 overdue | penile cancer | Jiyan Liu | Recruiting | No outcome recorded |
| Phase 1 | NCT04868344 | May 2018 → Mar 2021 | cancer | Shanghai Miracogen Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07685470 | Jun 2026 → May 2028 expected | pancreatic ductal adenocarcinoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07542717 | Apr 2026 → Mar 2028 expected | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05688605 | Jun 2022 → May 2025 | cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 242 trials | ||||||
| Phase 2 | NCT07303283 | Sep 2026 → Aug 2030 expected | nasopharyngeal carcinoma | Kai Hu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07707167 | Aug 2026 → Jan 2028 expected | head and neck squamous cell carcinoma | Jiangsu Cancer Institute & Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07712029 | Aug 2026 → Aug 2028 expected | refractory malignant neoplasm | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07686926 | Aug 2026 → Jul 2028 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07518979 | Jul 2026 → May 2028 expected | penile cancer | Jiyan Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07692334 | Jul 2026 → Sep 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | West China Second University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07627321 | Jul 2026 → Jul 2028 expected | non-small cell lung carcinoma | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07586124 | Jul 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | Lepu Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07649980 | Jul 2026 → Jul 2029 expected | biliary tract cancer | HuiKai Li | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07665190 | Jul 2026 → Oct 2027 expected | hypopharynx squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07683507 | Jul 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | Feng Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07677475 | Jun 2026 → Jan 2029 expected | head and neck squamous cell carcinoma | Dongguan People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07632339 | Jun 2026 → Jun 2028 expected | head and neck cancer | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07424664 | Jun 2026 → Mar 2027 expected | cervical cancer, vaginal neoplasm, vulva cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT07490119 | Jun 2026 → Jun 2028 expected | colorectal cancer, susceptibility to, 4 | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07267338 | Jun 2026 → Dec 2027 expected | nasopharyngeal carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07628855 | May 2026 → Aug 2028 expected | hereditary nonpolyposis colon cancer | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07579598 | May → Dec 2026 expected | salivary gland adenoid cystic carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07497919 | May 2026 → May 2029 expected | penile cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07522879 | May 2026 → Oct 2028 expected | adenoid cystic carcinoma, nasal cavity and paranasal sinus carcinoma | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07589049 | May 2026 → Nov 2027 expected | head and neck squamous cell carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07555860 | Apr 2026 → Dec 2027 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07536789 | Apr 2026 → Apr 2028 expected | hepatocellular carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07531979 | Apr 2026 → Mar 2027 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07545083 | Apr 2026 → Mar 2027 expected | head and neck squamous cell carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07464366 | Mar 2026 → May 2028 expected | salivary gland carcinoma | Ji Dongmei | Recruiting | No outcome recorded |
| Phase 2 | NCT07514533 | Mar 2026 → Dec 2027 expected | cholangiocarcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07496190 | Feb 2026 → Feb 2032 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07381075 | Feb 2026 → Oct 2028 expected | head and neck squamous cell carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07381699 | Feb 2026 → Feb 2028 expected | nasopharyngeal carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07393477 | Feb 2026 → Jul 2028 expected | head and neck squamous cell carcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07394244 | Jan 2026 → Dec 2028 expected | skin squamous cell carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07331428 | Jan 2026 → Dec 2027 expected | nasopharyngeal carcinoma | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06959108 | Oct 2025 → Jun 2029 expected | head and neck squamous cell carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Recruiting | No outcome recorded |
| Phase 2 | NCT07235566 | Apr 2025 → Apr 2029 expected | thyroid cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06509997 | Aug 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | Lei Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06530914 | Aug 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | Lei Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05126719 | Apr 2023 → Dec 2024 overdue | nasopharyngeal carcinoma | Shanghai Miracogen Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05188209 | May 2021 → Mar 2023 | gastroesophageal cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04838964 | Apr 2021 → Oct 2024 | biliary tract cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04868162 | Apr 2021 → Jun 2026 overdue | head and neck squamous cell carcinoma | Shanghai Miracogen Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04838548 | Sep 2020 → Dec 2022 | non-small cell lung carcinoma | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07598318 | May 2026 → Dec 2027 expected | cholangiocarcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07705243 | Jul 2026 → Jul 2028 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07524413 | Apr 2026 → Apr 2030 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07459296 | Mar 2026 → Apr 2030 expected | nasopharyngeal carcinoma | First Affiliated Hospital of Guangxi Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT07481799 | Feb 2026 → Feb 2029 expected | metastatic malignant neoplasm | Ming-Yuan Chen | Recruiting | No outcome recorded |
| Phase 3 | NCT07524452 | Feb 2026 → Feb 2031 expected | head and neck squamous cell carcinoma | Ming-Yuan Chen | Recruiting | No outcome recorded |
| Phase 3 | NCT06976190 | May 2025 → May 2029 expected | nasopharyngeal carcinoma | Shanghai Miracogen Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05751512 | Mar 2023 → Aug 2025 | head and neck squamous cell carcinoma | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 60 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Becotatug vedotin | “BACKGROUND: Recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) patients who failed platinum-based chemotherapy, with or without PD-1/L1 inhibitors, face limited...” PMID 41720100 ↗ Feb 202640“Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)” NCT07545083 ↗ “MRG003 [Becotatug vedotin, an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC)]” NCT07542717 ↗ “Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma” NCT07536789 ↗ “1. Becotatugvedotin: 2mg/kg, intravenous, every 3 weeks, on day 1” NCT07514533 ↗ “MRG003 (Becotatug Vedotin) Plus Toripalimab Versus Toripalimab” NCT07677475 ↗ |
| Known as | Anti-egfr adc mrg003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068210 ↗ |
| Known as | Becotatug vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068210 ↗ |
| Known as | Becotatug vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068210 ↗ |
| Known as | MRG003 | “MRG003 is administered intravenously at 2.3 mg/kg on day 1 of each cycle, every three weeks, as monotherapy, for up to two years or until treatment discontinuation criteria are met.” NCT07464366 ↗30“Becotatug vedotin (MRG003) is an epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate (ADC) conjugated with monomethyl auristatin E (MMAE).” NCT07692334 ↗ “Neoadjuvant Phase: All subjects will receive 2 cycles of Becotatug vedotin (MRG003): 2.0 mg/kg, Q3W, D1, IV(60 ± 15 min, first cycle infusion ≥ 60 min).” NCT07707167 ↗ “Becotatug vedotin (MRG003) is an antibody-drug conjugate that carries the payload monomethyl auristatin E (MMAE), a microtubule inhibitor.” NCT07481799 ↗ “Becotatug vedotin (also known as MRG003) is an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR).” NCT07522879 ↗ “Becotatug Vedotin (MRG003): The initial dosage is 2.3 mg/kg, administered intravenously every three weeks per treatment cycle.” NCT07579598 ↗ “Becotatug vedotin (MRG003): Administered from Cycle 1 to Cycle 4 at a dose of 2.0 mg/kg, once every 3 weeks on D1.” NCT07627321 ↗ “MRG003 [Becotatug vedotin, an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC)]” NCT07542717 ↗ “Participants receive Becotatug vedotin (MRG003) in combination with Cisplatin and concurrent radiotherapy.” NCT07697040 ↗ “Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma” NCT07536789 ↗ “Becotatug Vedotin (MRG003) 2.0 mg/kg, intravenous infusion, Day 1 (3 cycles, Q3W)” NCT07524413 ↗ “Study Drug: Becotatug Vedotin (MRG003) for Injection” NCT07584499 ↗ “Becotatug Vedotin(MRG003)” NCT07665190 ↗ |
| Known as | Vebecototagene Autoteucovaline | “MRG003 (Vebecototagene Autoteucovaline), an anti-EGFR antibody-drug conjugate” NCT07677475 ↗ |
| Action | Deplete | “thereby inducing targeted cell death” NCT07424664 ↗ |
| Modality | Monoclonal antibody | “humanized immunoglobulin G1 monoclonal antibody” PMID 35511148 ↗ Jul 2022 |
| Route | Intravenous | “Administered intravenously” NCT04838548 ↗ |
| Target | EGFR | “anti-epidermal growth factor receptor (EGFR)” PMID 35511148 ↗ Jul 2022 |